Induction of therapeutic senescence in vemurafenib-resistant melanoma by extended inhibition of CDK4/6 A Yoshida, EK Lee, JA Diehl Cancer research 76 (10), 2990-3002, 2016 | 166 | 2016 |
MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer R De Leeuw, C McNair, MJ Schiewer, NP Neupane, LJ Brand, ... Clinical Cancer Research 24 (17), 4201-4214, 2018 | 119 | 2018 |
The AMBRA1 E3 ligase adaptor regulates the stability of cyclin D AC Chaikovsky, C Li, EE Jeng, S Loebell, MC Lee, CW Murray, R Cheng, ... Nature 592 (7856), 794-798, 2021 | 110 | 2021 |
A PERK–miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival Y Bu, A Yoshida, N Chitnis, BJ Altman, F Tameire, A Oran, V Gennaro, ... Nature cell biology 20 (1), 104-115, 2018 | 109 | 2018 |
COP1 targets C/EBPα for degradation and induces acute myeloid leukemia via Trib1 A Yoshida, J Kato, I Nakamae, N Yoneda-Kato Blood, The Journal of the American Society of Hematology 122 (10), 1750-1760, 2013 | 96 | 2013 |
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma S Qie, A Yoshida, S Parnham, N Oleinik, GC Beeson, CC Beeson, ... Nature Communications 10 (1), 1296, 2019 | 93 | 2019 |
CSN5 specifically interacts with CDK2 and controls senescence in a cytoplasmic cyclin E-mediated manner A Yoshida, N Yoneda-Kato, J Kato Scientific reports 3 (1), 1054, 2013 | 58 | 2013 |
PERK is a haploinsufficient tumor suppressor: gene dose determines tumor-suppressive versus tumor promoting properties of PERK in melanoma D Pytel, Y Gao, K Mackiewicz, YV Katlinskaya, KA Staschke, ... PLoS genetics 12 (12), e1006518, 2016 | 54 | 2016 |
SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors A Yoshida, Y Bu, S Qie, J Wrangle, ER Camp, ES Hazard, G Hardiman, ... Science advances 5 (9), eaax6352, 2019 | 45 | 2019 |
Stable Form of JAB1 Enhances Proliferation and Maintenance of Hematopoietic Progenitors∗ M Mori, N Yoneda-Kato, A Yoshida, J Kato Journal of Biological Chemistry 283 (43), 29011-29021, 2008 | 44 | 2008 |
CSN5/Jab1 controls multiple events in the mammalian cell cycle A Yoshida, N Yoneda-Kato, M Panattoni, R Pardi, J Kato FEBS letters 584 (22), 4545-4552, 2010 | 36 | 2010 |
Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines K Noguchi, AC Dalton, BV Howley, BJ McCall, A Yoshida, JA Diehl, ... PLoS One 12 (5), e0177830, 2017 | 28 | 2017 |
CDK4/6 inhibitor: from quiescence to senescence A Yoshida, JA Diehl Oncoscience 2 (11), 896–897, 2015 | 26 | 2015 |
Consequence of the tumor‐associated conversion to cyclin D1b MA Augello, LD Berman‐Booty, R Carr 3rd, A Yoshida, JL Dean, ... EMBO Molecular Medicine 7 (5), 628-647, 2015 | 25 | 2015 |
Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3 A Yoshida, J Choi, HR Jin, Y Li, S Bajpai, S Qie, JA Diehl Oncogene 40 (2), 292-306, 2021 | 24 | 2021 |
Fibril formation of hsp10 homologue proteins and determination of fibril core regions: differences in fibril core regions dependent on subtle differences in amino acid sequence H Yagi, A Sato, A Yoshida, Y Hattori, M Hara, J Shimamura, I Sakane, ... Journal of molecular biology 377 (5), 1593-1606, 2008 | 16 | 2008 |
Depletion of CSN5 inhibits Ras-mediated tumorigenesis by inducing premature senescence in p53-null cells I Tsujimoto, A Yoshida, N Yoneda-Kato, J Kato FEBS letters 586 (24), 4326-4331, 2012 | 12 | 2012 |
The COP1 E3-ligase interacts with FIP200, a key regulator of mammalian autophagy S Kobayashi, N Yoneda-Kato, N Itahara, A Yoshida, J Kato BMC biochemistry 14, 1-8, 2013 | 11 | 2013 |
Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss A Yoshida, P Phillips-Mason, V Tarallo, S Avril, C Koivisto, G Leone, ... Oncogene 41 (15), 2187-2195, 2022 | 6 | 2022 |
Inhibition of glutaminase elicits senolysis in therapy-induced senescent melanoma cells J Kim, B Brunetti, A Kumar, A Mangla, K Honda, A Yoshida Cell Death & Disease 15 (12), 902, 2024 | | 2024 |